Actinium Pharmaceuticals, Inc. revenue

Actinium Pharmaceuticals, Inc.'s revenue was $90,000 in fiscal 2025, up 11.1% on the year before. Since fiscal 2021 ($1.1m) it has grown at a compound -57.2% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Actinium Pharmaceuticals, Inc.: revenue history, annual
Fiscal year	2010Dec 2010	2011Dec 2011	2021Dec 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Revenue	0	0	1,144	1,030	81	90
Growth on the year before	—	—	—	−10.0%	−92.1%	+11.1%
Gross profit	0	0	244	—	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Actinium Pharmaceuticals, Inc.: revenue history, quarterly
Quarter	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Revenue	0	1	0	0	0	0	0	35
Growth on the same quarter a year before	—	—	—	—	−100.0%	−90.4%	−100.0%	+>999%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Actinium Pharmaceuticals, Inc.	$1.0m	-10.0%	—
Shattuck Labs, Inc.	$1.0m	-66.6%	5.2%
Medicinova Inc	$920,481	875.7%	—
Longeveron Inc.	$1.2m	-42.7%	10.4%
Dare Bioscience, Inc.	$1.4m	4366.5%	—
Cartesian Therapeutics, Inc.	$1.5m	44.0%	-68.8%

Compare with peers

Head to head: ATNM vs STTK ATNM vs MNOV ATNM vs LGVN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Actinium Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Actinium Pharmaceuticals, Inc.